Sun Pharmaceutical Industries (SUNPHARMA) Investor presentation summary

Business overview and global presence

• Operates in over 100 countries with 43,000+ employees and 40 manufacturing facilities.

• Largest pharmaceutical company in India with 8.3% market share and 12th largest in US generics.

• Diversified revenue: India 33%, US 31%, Emerging Markets 18%, Rest of World 14%, API & Others 4%.

• Focus on innovative medicines, branded generics, generics, and APIs.

• Expanding presence in ex-US developed markets and emerging markets.

Financial performance and growth

• FY25 sales reached Rs 520 Bn, with a 19% CAGR in sales from FY10 to FY25.

• EBITDA margin at 29% in FY25, with adjusted net profit margin at 22.8%.

• Market capitalization at US $45 Bn as of August 2025.

• Free cash flow CAGR of 24% from FY10 to FY25.

• Strong profitability and best-in-class margins compared to top Indian pharma peers.

Business segments and operations

• US business: 31% of FY25 revenues, 12th largest generics company, robust pipeline with 661 ANDAs and 70 NDAs filed.

• India business: 33% of FY25 revenues, market leader in chronic and acute segments, 30 brands in top 300.

• Emerging Markets: 18% of FY25 revenues, presence in 80+ countries, focus on branded generics.

• Rest of World: 14% of FY25 revenues, expanding innovative and hospital product portfolio.

• API: 4% of FY25 revenues, 400+ APIs, strong backward integration.